Amicus Therapeutics: a Biopharmaceutical Company that Offers Cutting-edge Solutions

Amicus Therapeutics is an American pharmaceutical company whose headquarters is in Cranbury, New Jersey. This company was formed in 2002, and its chief executive officer is John Crowley. Amicus Therapeutics is a public company and was listed on NASDAQ in 2007. Other key officials in the company include Bradley Campbell, who serves as the chief operations officer, and William Baird, who is the chief financial officer. Amicus Therapeutics boasts over a million dollar net worth and has over 100 employees. This firm has survived economic downturns and continues to conquer new markets while developing world-class products.

 

About Amicus Therapeutics

 

Amicus Therapeutics conducts research on rare diseases, which are commonly known as lysosomal storage disorders. This company manufactures products based on the Chaperone-Advanced Replacement Therapy (CHART). For years, this company has focused its resources on the development of enzyme replacement therapies (ERTs). Amicus Therapeutics was recognized in 2014 for possessing a broad range portfolio of pharmacological chaperones in the biopharmaceutical industry. This company’s most popular product is migalastat commonly known as Galafold, which is used in the treatment of Fabry diseases. This compound is designed to stabilize endogenous mutant galactosidase compounds. Amicus Therapeutics has also worked in collaboration with the major players in the pharmaceutical industry, including JCR Pharmaceuticals and GlaxoSmithKline. This cooperation was aimed at researching on co-formulation of the conjugate alpha-galactosidase. In 2008, Amicus Therapeutics moved its operations from New Jersey to a facility in San Diego.

 

Amicus Therapeutics source of funding

 

This company extraordinary works have been recognized globally, and in 2010, Amicus Therapeutics received $500,000 in research grants. This funding was issued by the Michel J (GoogleFinance). Fox Foundation to support a collaborative research with David Geffen School of Medicine at UCLA. Amicus Therapeutics is also the recipient of the $210,300 grant, which was issued by the Alzheimer’s Drug Discovery Foundation. Other donors that have funded this company include Canaan Partners, Radius Ventures, and New Enterprise Associates. Amicus Therapeutics has tried to expand its business across the United States. In 2013, it acquired Callidus Biopharma. This acquisition led to the obtaining of a replacement therapy used to treat Pompe Disease. Amicus Therapeutics also purchased Scioderm in 2015 for $947 million.

More of Amicus Therapeutics at Facebook | Twitter | Crunchbase